Navigation Links
Amgen Announces 31 Percent Increase In 2013 First Quarter Dividend And Increase In Its Share Repurchase Authorization
Date:12/13/2012

patent applications may be challenged, invalidated or circumvented by our competitors. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock.

CONTACT: Amgen, Thousand Oaks
Ashleigh Koss, 805-313-6151 (media)
Arvind Sood, 805-447-1060 (investors)

(Logo: http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)


'/>"/>
SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
2. Four Californians Selected As Breakaway from Cancer® Champions To Be Honored During Amgen Tour of California
3. Amgen to Present at the Baird Growth Stock Conference
4. Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars
5. Amgens BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
6. Amgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial
7. Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
8. Amgen Completes Acquisition of KAI Pharmaceuticals
9. Amgens Second Quarter 2012 Revenues Increased 13 Percent To $4.5 Billion And Adjusted Earnings Per Share (EPS) Increased 34 Percent To $1.83
10. Amgen Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer
11. Amgen To Present At The Baird Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 As health officials across the ... select Meijer pharmacies in Michigan will ... eligible patients, enabling Meijer pharmacists to administer tests and, in ... by a physician participating in the study. The ...
(Date:1/15/2014)... 2014 Shire plc (LSE: SHP, NASDAQ: ... Trading (OFT) approval condition to the announced tender offer for all ... As a result of the waiver, the transaction is no ... tender offer on January 24, 2014 following the currently scheduled expiration ...
(Date:1/15/2014)... 2014 Tegra Medical is very pleased to announce the ... new Chief Executive Officer.  Mark was promoted from his current ... the company,s four facilities in Massachusetts , ... joined Tegra Medical in 2012 with 20+ years of broad-based ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
(Date:4/17/2014)... of chronic inflammation in non-cancerous prostate tissue may have ... than those with no inflammation, according to results of ... Hopkins Kimmel Cancer Center. , The link between persistent ... so-called high-grade prostate cancer those with a Gleason ... of the most aggressive and rapidly growing prostate cancers. ...
(Date:4/17/2014)... new pain relief targets that could be used ... at King,s College London made the discovery when ... periphery of the body. , Dr Marzia Malcangio ... underlying pain generation and our findings could help ... , One potential side effect of some chemotherapy ...
(Date:4/17/2014)... published today in PLOS Pathogens , children who ... common can mount an immune response to infection with ... bouts of high fever and illness and partially control ... findings may help researchers develop future interventions that prevent ... , Each year, approximately 200 million cases of malaria ...
(Date:4/17/2014)... of California, San Diego School of Medicine report that ... a recent major loss are more likely to be ... study is published in this month,s issue of the ... compassionate behaviors are associated with better health and well-being ... ways to improve the outcomes of individuals whose deficits ...
(Date:4/17/2014)... review published in the April issue of Immunity ... Institute for Medical Research, says it,s time to take ... to treating sepsis, which kills millions worldwide every ... when molecules released into the bloodstream to fight an ... is necessary for maintaining good health without inflammation, ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:New pain relief targets discovered 2Health News:Study sheds light on how the immune system protects children from malaria 2Health News:The ilk of human kindness 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2
... 29, 2007 Traditionally, clinicians have relied on ... visits as the primary means of assessing patients ... could arise if important symptoms go unreported during ... A new study by researchers at Memorial Sloan-Kettering ...
... Nov. 29 Today, the Infectious,Diseases Institute (IDI) ... leader in HIV/AIDS prevention and treatment, as the ... joining IDI, Dr. Coutinho spent six years leading ... care and treatment,organization in Africa. His impressive accomplishments ...
... New MEDEX Global Group/Harvard Medical International Website goes beyond, ... the Lesser-Known Factors ... Healthcare, BALTIMORE, Nov. 29 Determining health risks ... incredibly complex.,According to the just published MEDEX 360m International ...
... Nov. 29 AtriCure, Inc.,(Nasdaq: ATRC ), a ... announced today that David J. Drachman, President and,Chief Executive ... Markets,2007 Healthcare Conference at the Millennium Broadway Hotel in ... ET., A live web cast and recording of ...
... 29 Specialty chemicals,maker Albemarle Corporation (NYSE: ... (also referred to as DBM, methylene dibromide, or,MDB) ... 2007, or as contracts allow., (Logo: ... needed to cover higher costs, in particular,higher raw ...
... on seizures linked to lamotrigine use, research shows , ... levels of the drug lamotrigine in pregnant women with epilepsy ... research shows. , Lamotrigine, an epilepsy drug, is taken by ... of causing birth defects. However, the drug has also been ...
Cached Medicine News:Health News:Cancer patients may benefit from reporting symptoms online in real time 2Health News:Cancer patients may benefit from reporting symptoms online in real time 3Health News:Cancer patients may benefit from reporting symptoms online in real time 4Health News:Infectious Diseases Institute Appoints Alex Coutinho, M.D as Executive Director 2Health News:Infectious Diseases Institute Appoints Alex Coutinho, M.D as Executive Director 3Health News:MEDEX 360m Rates the State of Global Medical Care for Travelers 2Health News:AtriCure to Present at BMO Capital Markets 2007 Healthcare Conference 2Health News:Albemarle to Raise Prices of Dibromomethane 2Health News:Tracking Drug Levels Helps Pregnant Women With Epilepsy 2
... Cardiovascular Patch utilizes advanced fluoropolymer ... around penetrating suture and decrease ... much as 88 percent. This ... retention, multi-directional strength and low ...
... surgery, modified Blalock-Taussig shunts provide palliation of ... GORE-TEX Vascular Grafts configured for Pediatric Shunts ... use as shunts in pediatric cardiac procedures. ... ease of implantation and take-down at total ...
... techniques for vascular surgery, and the accompanying ... specialized types of graft be developed. Grafts ... biocompatible, but also available in varying sizes ... Vascular Graft has long been the prosthetic ...
... have met the challenges of the most ... Recognized for exceptional performance and quality, they ... worldwide. These grafts require no preclotting, resist ... assure utmost thrombectomy safety. Gore vascular grafts ...
Medicine Products: